Madrigal is eying an expansion of MASH blockbuster Rezdiffra’s capabilities via combination with precision siRNA gene ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025 and reviewed ...
Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results